Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 41 | 2025 | 264 | 8.440 |
Why?
| | Chemical and Drug Induced Liver Injury | 16 | 2023 | 146 | 4.690 |
Why?
| | Analgesics, Non-Narcotic | 22 | 2025 | 126 | 4.610 |
Why?
| | Drug Overdose | 32 | 2025 | 362 | 4.050 |
Why?
| | Poison Control Centers | 13 | 2025 | 83 | 3.420 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 2270 | 3.130 |
Why?
| | Poisoning | 17 | 2017 | 119 | 2.880 |
Why?
| | Acetylcysteine | 12 | 2023 | 146 | 2.550 |
Why?
| | Alanine Transaminase | 14 | 2023 | 154 | 2.510 |
Why?
| | Cocaine | 10 | 2011 | 171 | 2.340 |
Why?
| | Cannabis | 9 | 2020 | 520 | 2.220 |
Why?
| | Prescription Drugs | 9 | 2018 | 114 | 2.150 |
Why?
| | Antidotes | 10 | 2023 | 148 | 1.630 |
Why?
| | Legislation, Drug | 5 | 2017 | 80 | 1.430 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 1126 | 1.430 |
Why?
| | Cysteine | 4 | 2017 | 212 | 1.310 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 210 | 1.280 |
Why?
| | Marijuana Use | 4 | 2021 | 223 | 1.150 |
Why?
| | Medication Errors | 5 | 2015 | 97 | 1.120 |
Why?
| | Pain | 9 | 2020 | 781 | 1.060 |
Why?
| | Emergency Medicine | 6 | 2019 | 258 | 1.050 |
Why?
| | Male | 103 | 2022 | 71501 | 1.050 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 136 | 1.040 |
Why?
| | Humans | 156 | 2025 | 143560 | 1.040 |
Why?
| | Drug Packaging | 2 | 2017 | 43 | 1.020 |
Why?
| | Toxicology | 4 | 2021 | 46 | 1.020 |
Why?
| | Medication Reconciliation | 2 | 2016 | 30 | 0.930 |
Why?
| | Female | 96 | 2023 | 77252 | 0.910 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2056 | 0.910 |
Why?
| | Adult | 73 | 2022 | 40012 | 0.900 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 32 | 0.860 |
Why?
| | Spider Bites | 5 | 2019 | 7 | 0.860 |
Why?
| | Antivenins | 5 | 2019 | 29 | 0.860 |
Why?
| | Diphenhydramine | 4 | 2023 | 38 | 0.840 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.830 |
Why?
| | Thiazoles | 4 | 2009 | 134 | 0.810 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 15 | 0.800 |
Why?
| | Spider Venoms | 4 | 2019 | 9 | 0.800 |
Why?
| | Benzodiazepines | 6 | 2023 | 163 | 0.790 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 30 | 0.770 |
Why?
| | Lorazepam | 3 | 2023 | 25 | 0.760 |
Why?
| | Heart Arrest | 8 | 2018 | 399 | 0.750 |
Why?
| | Young Adult | 30 | 2020 | 13972 | 0.730 |
Why?
| | Middle Aged | 54 | 2022 | 35343 | 0.720 |
Why?
| | Physostigmine | 2 | 2020 | 13 | 0.710 |
Why?
| | Seizures | 6 | 2011 | 454 | 0.710 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 352 | 0.710 |
Why?
| | Emergency Treatment | 4 | 2015 | 128 | 0.710 |
Why?
| | Black Widow Spider | 4 | 2019 | 7 | 0.700 |
Why?
| | Referral and Consultation | 2 | 2020 | 828 | 0.700 |
Why?
| | Medical History Taking | 3 | 2018 | 118 | 0.700 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 61 | 0.690 |
Why?
| | Piperazines | 4 | 2009 | 393 | 0.690 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 270 | 0.690 |
Why?
| | Delirium | 2 | 2020 | 105 | 0.680 |
Why?
| | Abdominal Pain | 2 | 2019 | 144 | 0.660 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 139 | 0.640 |
Why?
| | Suicide, Attempted | 5 | 2012 | 398 | 0.630 |
Why?
| | Back Pain | 1 | 2020 | 52 | 0.630 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 138 | 0.630 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 557 | 0.620 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 86 | 0.620 |
Why?
| | Patient Handoff | 1 | 2020 | 39 | 0.600 |
Why?
| | Buprenorphine | 2 | 2020 | 184 | 0.600 |
Why?
| | Haloperidol | 1 | 2019 | 33 | 0.600 |
Why?
| | Ketorolac | 1 | 2019 | 25 | 0.600 |
Why?
| | Retrospective Studies | 31 | 2023 | 16740 | 0.590 |
Why?
| | Emergency Medical Services | 5 | 2025 | 685 | 0.590 |
Why?
| | Social Work | 1 | 2020 | 86 | 0.580 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 22 | 0.580 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.560 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 182 | 0.560 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 56 | 0.560 |
Why?
| | Vomiting | 6 | 2019 | 129 | 0.550 |
Why?
| | Colorado | 15 | 2021 | 4658 | 0.550 |
Why?
| | Hypotension | 2 | 2022 | 126 | 0.540 |
Why?
| | Prospective Studies | 18 | 2023 | 7900 | 0.540 |
Why?
| | Drug Storage | 2 | 2017 | 53 | 0.530 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1113 | 0.530 |
Why?
| | Accidents, Home | 1 | 2017 | 33 | 0.520 |
Why?
| | Child | 28 | 2023 | 22725 | 0.520 |
Why?
| | Medical Marijuana | 2 | 2019 | 124 | 0.510 |
Why?
| | Cannabinoids | 3 | 2017 | 181 | 0.510 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 92 | 0.510 |
Why?
| | Plant Preparations | 2 | 2015 | 37 | 0.510 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.500 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 239 | 0.500 |
Why?
| | Electronic Health Records | 4 | 2024 | 1163 | 0.500 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 52 | 0.490 |
Why?
| | Hypocalcemia | 1 | 2016 | 36 | 0.490 |
Why?
| | Health Records, Personal | 1 | 2016 | 29 | 0.480 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 65 | 0.480 |
Why?
| | Blood Proteins | 1 | 2017 | 247 | 0.470 |
Why?
| | Mobile Applications | 1 | 2018 | 192 | 0.470 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 29 | 0.460 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 257 | 0.460 |
Why?
| | Antidepressive Agents | 2 | 2012 | 243 | 0.460 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1362 | 0.450 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 49 | 0.450 |
Why?
| | Liver | 6 | 2022 | 1864 | 0.450 |
Why?
| | Electrocardiography | 5 | 2013 | 630 | 0.440 |
Why?
| | Treatment Outcome | 18 | 2020 | 11365 | 0.430 |
Why?
| | Infant | 13 | 2023 | 9981 | 0.430 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 98 | 0.420 |
Why?
| | Child, Preschool | 13 | 2018 | 11737 | 0.420 |
Why?
| | Crime | 2 | 2011 | 60 | 0.410 |
Why?
| | Observer Variation | 3 | 2010 | 361 | 0.410 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.400 |
Why?
| | Energy Drinks | 1 | 2013 | 3 | 0.400 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 11 | 0.400 |
Why?
| | Bradycardia | 1 | 2013 | 52 | 0.390 |
Why?
| | Poisons | 2 | 2023 | 20 | 0.390 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 348 | 0.390 |
Why?
| | Plasmapheresis | 1 | 2013 | 24 | 0.390 |
Why?
| | Accidents | 1 | 2013 | 45 | 0.390 |
Why?
| | Diet Surveys | 1 | 2013 | 93 | 0.390 |
Why?
| | Amphotericin B | 1 | 2013 | 37 | 0.390 |
Why?
| | Hematemesis | 1 | 2012 | 4 | 0.390 |
Why?
| | Double-Blind Method | 7 | 2020 | 2017 | 0.390 |
Why?
| | Adolescent | 27 | 2020 | 22482 | 0.390 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 86 | 0.390 |
Why?
| | Foreign Bodies | 2 | 2011 | 108 | 0.380 |
Why?
| | Phytotherapy | 1 | 2013 | 82 | 0.380 |
Why?
| | Stomach Diseases | 1 | 2012 | 20 | 0.380 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.380 |
Why?
| | beta-Alanine | 1 | 2012 | 24 | 0.380 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 51 | 0.380 |
Why?
| | Citalopram | 1 | 2012 | 34 | 0.370 |
Why?
| | Liver Function Tests | 7 | 2020 | 107 | 0.370 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 773 | 0.370 |
Why?
| | Antithrombins | 1 | 2012 | 70 | 0.370 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.360 |
Why?
| | Antifungal Agents | 1 | 2013 | 147 | 0.360 |
Why?
| | Thiophenes | 1 | 2012 | 128 | 0.360 |
Why?
| | C-Peptide | 2 | 2010 | 171 | 0.360 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.350 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2417 | 0.350 |
Why?
| | Anaphylaxis | 2 | 2012 | 104 | 0.350 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 9 | 0.350 |
Why?
| | Charcoal | 4 | 2006 | 27 | 0.350 |
Why?
| | Dronabinol | 4 | 2021 | 244 | 0.350 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 423 | 0.350 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4522 | 0.350 |
Why?
| | Aged | 27 | 2019 | 25322 | 0.350 |
Why?
| | Temperance | 2 | 2010 | 21 | 0.350 |
Why?
| | Benzimidazoles | 1 | 2012 | 193 | 0.350 |
Why?
| | Alcohol Drinking | 4 | 2012 | 852 | 0.340 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.340 |
Why?
| | Administration, Intravenous | 4 | 2016 | 173 | 0.340 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 24 | 0.340 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 724 | 0.340 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 577 | 0.340 |
Why?
| | Brain Edema | 1 | 2011 | 63 | 0.340 |
Why?
| | Amitriptyline | 2 | 2001 | 24 | 0.340 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 110 | 0.330 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3380 | 0.330 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 178 | 0.330 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 141 | 0.330 |
Why?
| | Immunologic Factors | 2 | 2019 | 251 | 0.330 |
Why?
| | Liver Failure | 1 | 2011 | 82 | 0.320 |
Why?
| | Aged, 80 and over | 15 | 2018 | 8072 | 0.320 |
Why?
| | Burns | 2 | 2015 | 360 | 0.320 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 7 | 0.320 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 12 | 0.320 |
Why?
| | Propylene Glycol | 1 | 2010 | 9 | 0.320 |
Why?
| | Barium | 1 | 2009 | 26 | 0.320 |
Why?
| | Population Surveillance | 1 | 2013 | 488 | 0.310 |
Why?
| | Explosive Agents | 1 | 2009 | 7 | 0.310 |
Why?
| | Time Factors | 12 | 2020 | 7032 | 0.310 |
Why?
| | Imines | 2 | 2022 | 6 | 0.310 |
Why?
| | Hypokalemia | 1 | 2009 | 24 | 0.310 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.310 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 95 | 0.310 |
Why?
| | United States | 18 | 2025 | 15554 | 0.310 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.300 |
Why?
| | Warfarin | 1 | 2010 | 168 | 0.300 |
Why?
| | Deception | 1 | 2009 | 19 | 0.300 |
Why?
| | Liver Failure, Acute | 2 | 2023 | 66 | 0.300 |
Why?
| | Random Allocation | 3 | 2007 | 370 | 0.300 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 76 | 0.300 |
Why?
| | Benzoquinones | 2 | 2022 | 47 | 0.300 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5743 | 0.290 |
Why?
| | Odds Ratio | 7 | 2017 | 1060 | 0.290 |
Why?
| | Fluorides | 2 | 2016 | 49 | 0.290 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 6025 | 0.290 |
Why?
| | Risk Assessment | 8 | 2017 | 3577 | 0.290 |
Why?
| | Risk Factors | 9 | 2017 | 10644 | 0.290 |
Why?
| | Oximetry | 1 | 2009 | 130 | 0.290 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 92 | 0.290 |
Why?
| | Length of Stay | 3 | 2020 | 1279 | 0.280 |
Why?
| | Cyanoacrylates | 1 | 2008 | 4 | 0.280 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.280 |
Why?
| | Adhesives | 1 | 2008 | 15 | 0.280 |
Why?
| | Reference Values | 4 | 2017 | 811 | 0.270 |
Why?
| | Detergents | 1 | 2008 | 44 | 0.270 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 190 | 0.270 |
Why?
| | Intellectual Disability | 1 | 2009 | 178 | 0.270 |
Why?
| | Publishing | 1 | 2009 | 111 | 0.270 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.270 |
Why?
| | Hypoglycemia | 2 | 2010 | 473 | 0.270 |
Why?
| | Alcoholism | 4 | 2023 | 838 | 0.270 |
Why?
| | Animals | 22 | 2019 | 38010 | 0.260 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 642 | 0.260 |
Why?
| | Brugada Syndrome | 1 | 2007 | 14 | 0.260 |
Why?
| | Niacin | 1 | 2007 | 16 | 0.260 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 97 | 0.260 |
Why?
| | Diazepam | 1 | 2007 | 35 | 0.260 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 408 | 0.260 |
Why?
| | Vitamin B Complex | 1 | 2007 | 40 | 0.260 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.250 |
Why?
| | Pediatrics | 1 | 2015 | 1124 | 0.250 |
Why?
| | Specimen Handling | 1 | 2008 | 181 | 0.250 |
Why?
| | Thromboembolism | 1 | 2007 | 126 | 0.250 |
Why?
| | Pyrazoles | 2 | 2023 | 496 | 0.240 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 41 | 0.240 |
Why?
| | Analgesics | 4 | 2017 | 235 | 0.240 |
Why?
| | Nausea | 4 | 2014 | 112 | 0.240 |
Why?
| | Decontamination | 1 | 2006 | 32 | 0.240 |
Why?
| | Amiodarone | 1 | 2005 | 32 | 0.240 |
Why?
| | Self Report | 4 | 2021 | 878 | 0.230 |
Why?
| | Age Factors | 7 | 2017 | 3328 | 0.230 |
Why?
| | Intention | 1 | 2007 | 181 | 0.230 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 19 | 0.230 |
Why?
| | Venous Thrombosis | 1 | 2007 | 194 | 0.230 |
Why?
| | Eating | 4 | 2017 | 397 | 0.230 |
Why?
| | Anticoagulants | 1 | 2010 | 728 | 0.230 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.230 |
Why?
| | Epilepsy | 2 | 2020 | 372 | 0.220 |
Why?
| | Drug Utilization | 5 | 2014 | 166 | 0.220 |
Why?
| | Calcium | 3 | 2016 | 1183 | 0.220 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1672 | 0.220 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 70 | 0.220 |
Why?
| | Education, Medical | 2 | 2021 | 276 | 0.220 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 333 | 0.220 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 831 | 0.220 |
Why?
| | Coma | 2 | 2006 | 36 | 0.220 |
Why?
| | Databases, Factual | 1 | 2010 | 1465 | 0.220 |
Why?
| | Biomarkers | 7 | 2021 | 4241 | 0.210 |
Why?
| | Hospitals, Urban | 5 | 2021 | 137 | 0.210 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 116 | 0.200 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 43 | 0.200 |
Why?
| | Triage | 2 | 2025 | 252 | 0.200 |
Why?
| | Animal Experimentation | 1 | 2003 | 8 | 0.200 |
Why?
| | Case-Control Studies | 4 | 2022 | 3625 | 0.200 |
Why?
| | Calcium Chloride | 1 | 2003 | 11 | 0.200 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1984 | 0.200 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 214 | 0.200 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1394 | 0.190 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 115 | 0.190 |
Why?
| | Insulin | 3 | 2019 | 2497 | 0.190 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 18 | 0.190 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 287 | 0.190 |
Why?
| | Documentation | 1 | 2024 | 194 | 0.180 |
Why?
| | Placebos | 2 | 2014 | 195 | 0.180 |
Why?
| | Umbilical Cord | 2 | 2021 | 87 | 0.180 |
Why?
| | Desipramine | 1 | 2001 | 11 | 0.180 |
Why?
| | Longevity | 3 | 2009 | 175 | 0.180 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 100 | 0.180 |
Why?
| | Logistic Models | 3 | 2017 | 2107 | 0.180 |
Why?
| | Confidence Intervals | 4 | 2010 | 332 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 181 | 0.170 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 334 | 0.170 |
Why?
| | Research Design | 3 | 2006 | 1123 | 0.170 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2936 | 0.170 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 24 | 0.170 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 122 | 0.170 |
Why?
| | Fractures, Bone | 2 | 2017 | 413 | 0.170 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 203 | 0.170 |
Why?
| | Heart Atria | 1 | 2001 | 146 | 0.170 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 175 | 0.160 |
Why?
| | Acute Disease | 2 | 2019 | 1015 | 0.160 |
Why?
| | Myocardial Contraction | 1 | 2001 | 300 | 0.160 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 11 | 0.160 |
Why?
| | Droperidol | 1 | 1999 | 5 | 0.160 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 3 | 0.160 |
Why?
| | Lithium Carbonate | 1 | 1999 | 6 | 0.160 |
Why?
| | Wisconsin | 1 | 2020 | 100 | 0.160 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 4 | 0.160 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 26 | 0.150 |
Why?
| | Starch | 1 | 2019 | 22 | 0.150 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.150 |
Why?
| | Survival Analysis | 4 | 2010 | 1332 | 0.150 |
Why?
| | Nutritive Value | 1 | 2019 | 37 | 0.150 |
Why?
| | Healthy Volunteers | 2 | 2019 | 213 | 0.150 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 36 | 0.150 |
Why?
| | Geriatric Assessment | 2 | 2011 | 225 | 0.150 |
Why?
| | Snake Bites | 1 | 1999 | 24 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2021 | 209 | 0.150 |
Why?
| | Immune System | 1 | 2020 | 183 | 0.150 |
Why?
| | Administration, Oral | 4 | 2019 | 842 | 0.150 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.150 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 6 | 0.150 |
Why?
| | Community Health Workers | 1 | 2020 | 79 | 0.150 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 20 | 0.150 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.140 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 152 | 0.140 |
Why?
| | Metabolome | 1 | 2022 | 374 | 0.140 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1058 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 212 | 0.140 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 527 | 0.140 |
Why?
| | Mass Screening | 1 | 2007 | 1334 | 0.140 |
Why?
| | Cohort Studies | 7 | 2023 | 5891 | 0.140 |
Why?
| | Cannabidiol | 1 | 2020 | 131 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 229 | 0.140 |
Why?
| | Sex Factors | 5 | 2022 | 2092 | 0.140 |
Why?
| | Sulfasalazine | 1 | 1998 | 23 | 0.140 |
Why?
| | Drug Antagonism | 2 | 2009 | 10 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 406 | 0.130 |
Why?
| | Faculty, Medical | 1 | 2021 | 297 | 0.130 |
Why?
| | Dietary Fats | 1 | 2019 | 304 | 0.130 |
Why?
| | Dyspnea | 1 | 1999 | 259 | 0.130 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1452 | 0.130 |
Why?
| | Methotrexate | 1 | 1998 | 256 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 698 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 284 | 0.130 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 67 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 333 | 0.130 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 123 | 0.130 |
Why?
| | Incidence | 4 | 2013 | 2844 | 0.130 |
Why?
| | Survival Rate | 3 | 2013 | 2003 | 0.130 |
Why?
| | Ammonium Compounds | 1 | 2016 | 4 | 0.130 |
Why?
| | Mice | 8 | 2009 | 18378 | 0.130 |
Why?
| | Energy Intake | 1 | 2019 | 513 | 0.120 |
Why?
| | Simulation Training | 1 | 2018 | 132 | 0.120 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 303 | 0.120 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 117 | 0.120 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 62 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1043 | 0.120 |
Why?
| | Half-Life | 2 | 2019 | 147 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 217 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 24 | 0.120 |
Why?
| | Pain Management | 2 | 2017 | 405 | 0.120 |
Why?
| | Milk | 1 | 2016 | 124 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2086 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 76 | 0.110 |
Why?
| | Genetic Variation | 1 | 2020 | 1008 | 0.110 |
Why?
| | Fatal Outcome | 2 | 2013 | 313 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 80 | 0.110 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1838 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 252 | 0.110 |
Why?
| | Ondansetron | 1 | 2014 | 19 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 59 | 0.110 |
Why?
| | Models, Biological | 2 | 2015 | 1831 | 0.110 |
Why?
| | Patient Simulation | 1 | 2014 | 39 | 0.110 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 32 | 0.110 |
Why?
| | Hydrocodone | 1 | 2014 | 19 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 97 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 23 | 0.110 |
Why?
| | Oxycodone | 1 | 2014 | 48 | 0.110 |
Why?
| | Guanfacine | 1 | 2013 | 5 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 940 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1047 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 35 | 0.100 |
Why?
| | International Normalized Ratio | 2 | 2011 | 50 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 181 | 0.100 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.100 |
Why?
| | Food | 1 | 2015 | 161 | 0.100 |
Why?
| | Internship and Residency | 2 | 2014 | 1250 | 0.100 |
Why?
| | Prognosis | 3 | 2011 | 4152 | 0.100 |
Why?
| | Remote Consultation | 1 | 2014 | 63 | 0.100 |
Why?
| | Acute Pain | 1 | 2014 | 54 | 0.100 |
Why?
| | Indazoles | 1 | 2014 | 78 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 17 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2019 | 590 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 10 | 0.100 |
Why?
| | Pain Measurement | 4 | 2019 | 558 | 0.100 |
Why?
| | Dabigatran | 1 | 2012 | 29 | 0.100 |
Why?
| | Canada | 2 | 2025 | 433 | 0.100 |
Why?
| | Walking | 1 | 2017 | 557 | 0.100 |
Why?
| | Tachycardia | 1 | 2012 | 57 | 0.090 |
Why?
| | Chlorides | 1 | 2013 | 137 | 0.090 |
Why?
| | Sleep Stages | 1 | 2012 | 76 | 0.090 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.090 |
Why?
| | Data Collection | 2 | 2013 | 655 | 0.090 |
Why?
| | Marijuana Abuse | 1 | 2015 | 232 | 0.090 |
Why?
| | Mycoses | 1 | 2013 | 87 | 0.090 |
Why?
| | Sampling Studies | 1 | 2012 | 103 | 0.090 |
Why?
| | Arsenicals | 1 | 2012 | 30 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1207 | 0.090 |
Why?
| | Dizziness | 1 | 2012 | 95 | 0.090 |
Why?
| | Magnesium | 2 | 2004 | 156 | 0.090 |
Why?
| | Athletic Performance | 1 | 2013 | 85 | 0.090 |
Why?
| | Patient Discharge | 2 | 2016 | 923 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 60 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 372 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 90 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Levamisole | 1 | 2011 | 20 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 262 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 206 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 25 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 474 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2010 | 5308 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 52 | 0.090 |
Why?
| | Accidental Falls | 2 | 2011 | 234 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 576 | 0.080 |
Why?
| | Molecular Structure | 1 | 2012 | 505 | 0.080 |
Why?
| | Pharmacogenetics | 1 | 2012 | 167 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2015 | 587 | 0.080 |
Why?
| | Sports | 1 | 2013 | 222 | 0.080 |
Why?
| | Universities | 1 | 2013 | 455 | 0.080 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.080 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 12 | 0.080 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 15 | 0.080 |
Why?
| | Troponin | 1 | 2010 | 46 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 31 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 37 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 137 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 275 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 1003 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 240 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 88 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 25 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 18 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 20 | 0.080 |
Why?
| | Risperidone | 1 | 2009 | 30 | 0.080 |
Why?
| | Potassium | 1 | 2009 | 149 | 0.070 |
Why?
| | Role | 1 | 2009 | 30 | 0.070 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 138 | 0.070 |
Why?
| | Head Protective Devices | 1 | 2009 | 25 | 0.070 |
Why?
| | Quality Control | 1 | 2009 | 160 | 0.070 |
Why?
| | Dogs | 1 | 2010 | 427 | 0.070 |
Why?
| | Bibliometrics | 1 | 2009 | 59 | 0.070 |
Why?
| | Acidosis | 2 | 2006 | 105 | 0.070 |
Why?
| | Glutathione | 3 | 2022 | 373 | 0.070 |
Why?
| | Verapamil | 2 | 2014 | 40 | 0.070 |
Why?
| | Diarrhea | 1 | 2009 | 183 | 0.070 |
Why?
| | Body Temperature | 1 | 2009 | 224 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 460 | 0.070 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 311 | 0.070 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 279 | 0.070 |
Why?
| | Workload | 1 | 2010 | 164 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 52 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 5 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 2 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 20 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 85 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 12 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 28 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 22 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 533 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 195 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 459 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 79 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 90 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 59 | 0.070 |
Why?
| | Students | 1 | 2013 | 655 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1049 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 370 | 0.070 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 15 | 0.070 |
Why?
| | Laboratories | 1 | 2008 | 107 | 0.070 |
Why?
| | Polypharmacy | 1 | 2008 | 90 | 0.060 |
Why?
| | Tissue Distribution | 2 | 2019 | 330 | 0.060 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 104 | 0.060 |
Why?
| | Quinolones | 1 | 2009 | 180 | 0.060 |
Why?
| | Phosphates | 1 | 2008 | 178 | 0.060 |
Why?
| | Formates | 1 | 2006 | 15 | 0.060 |
Why?
| | Military Personnel | 1 | 2014 | 684 | 0.060 |
Why?
| | Research | 2 | 2011 | 438 | 0.060 |
Why?
| | Defibrillators | 1 | 2006 | 23 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1252 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2009 | 202 | 0.060 |
Why?
| | Methanol | 1 | 2006 | 45 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 60 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 434 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 50 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 698 | 0.060 |
Why?
| | Probability | 2 | 2010 | 308 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 51 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 73 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 17 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 325 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 148 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2313 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 156 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1946 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 82 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 51 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 176 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 42 | 0.060 |
Why?
| | Telemedicine | 1 | 2014 | 926 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 98 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1557 | 0.060 |
Why?
| | Risk | 1 | 2007 | 906 | 0.050 |
Why?
| | Spine | 1 | 2006 | 179 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2009 | 705 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2005 | 294 | 0.050 |
Why?
| | Water | 1 | 2008 | 471 | 0.050 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 19 | 0.050 |
Why?
| | Motivation | 1 | 2009 | 609 | 0.050 |
Why?
| | Blood Glucose | 2 | 2019 | 2316 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 270 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 3 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 8 | 0.050 |
Why?
| | Resuscitation | 1 | 2006 | 301 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 393 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 121 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 326 | 0.050 |
Why?
| | Survival | 1 | 2003 | 38 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 885 | 0.050 |
Why?
| | Urea | 1 | 2023 | 84 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 434 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 398 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 550 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 85 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 7153 | 0.050 |
Why?
| | Internet | 1 | 2007 | 698 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 383 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 74 | 0.050 |
Why?
| | Urban Population | 2 | 2019 | 491 | 0.050 |
Why?
| | Prevalence | 3 | 2015 | 2830 | 0.040 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 12 | 0.040 |
Why?
| | Neural Conduction | 1 | 2001 | 90 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2016 | 535 | 0.040 |
Why?
| | Hirudins | 1 | 2021 | 52 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2318 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 175 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 28 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 43 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | South America | 1 | 1999 | 56 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 52 | 0.040 |
Why?
| | Certification | 1 | 2020 | 121 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 55 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 676 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 15 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 116 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 89 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 39 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1314 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 37 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 859 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 601 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 135 | 0.040 |
Why?
| | North America | 1 | 1999 | 308 | 0.040 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 45 | 0.040 |
Why?
| | Laparotomy | 1 | 1998 | 116 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1369 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 180 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2001 | 335 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 517 | 0.030 |
Why?
| | Central Nervous System | 1 | 1999 | 269 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 704 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 583 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 103 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 898 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1324 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 278 | 0.030 |
Why?
| | Registries | 2 | 2010 | 2238 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1091 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 111 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 27 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 53 | 0.030 |
Why?
| | Observation | 1 | 2014 | 56 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 104 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 379 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 142 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 937 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 103 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 90 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 99 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 36 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2261 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 255 | 0.020 |
Why?
| | Salicylates | 1 | 2013 | 29 | 0.020 |
Why?
| | Urinalysis | 1 | 2013 | 80 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 69 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 163 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 365 | 0.020 |
Why?
| | Iron | 1 | 1994 | 345 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 70 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 71 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 30 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 8 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 61 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 20 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 161 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 1028 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 143 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1234 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 134 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 586 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 650 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 110 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 41 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 430 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 240 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 203 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 127 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 783 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 398 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 626 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 356 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 600 | 0.020 |
Why?
| | Safety | 1 | 2010 | 357 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 444 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1013 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 639 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 556 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 91 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 27 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 646 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1877 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 11 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 86 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1235 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 70 | 0.020 |
Why?
| | Metabolomics | 1 | 2012 | 715 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 47 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2006 | 134 | 0.020 |
Why?
| | European Union | 1 | 2005 | 11 | 0.010 |
Why?
| | Electric Countershock | 1 | 2006 | 115 | 0.010 |
Why?
| | Fever | 1 | 2007 | 310 | 0.010 |
Why?
| | Disaster Planning | 1 | 2006 | 96 | 0.010 |
Why?
| | Emergencies | 1 | 2006 | 180 | 0.010 |
Why?
| | Infant, Newborn | 2 | 2007 | 6366 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2006 | 597 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 202 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 173 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 863 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 171 | 0.010 |
Why?
| | Swine | 1 | 2006 | 837 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 114 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 506 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3211 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 70 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1064 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 13 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 198 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 4 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1755 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 22 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1117 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1824 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1813 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2531 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5610 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2804 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|